Caribou Biosciences (CRBU) investor relations material

Company and pipeline overview

• Focuses on CRISPR genome editing to develop allogeneic off-the-shelf CAR T-cell therapies for hematologic malignancies, with vispa-cel (CD19, non-Hodgkin lymphoma) pivotal-ready and CB-011 (BCMA, multiple myeloma) in phase I dose expansion.

• Vispa-cel demonstrated phase I data comparable to autologous CAR Ts, aiming to expand access to cell therapy for more patients.

• CB-011 showed response rates in phase I that approach those of auto CAR Ts, with durable responses in late-line, heavily pretreated patients; initial dose expansion data expected by year-end.

Technology platform and differentiation

• chRDNA platform offers improved editing specificity, enabling multi-edit strategies for immune cloaking and potency enhancements in CAR T products.

• Allogeneic CAR Ts use healthy donor T-cells, addressing rapid rejection and enhancing anti-tumor activity through edits like PD-1 knockout.

• Platform enables high-efficiency, high-specificity edits, setting programs apart from earlier competitors.

Market landscape and clinical positioning

• Only 25% of second-line large B-cell lymphoma patients in the US receive auto CAR T due to urgency and geographic barriers; vispa-cel's off-the-shelf nature addresses these gaps.

• Vispa-cel can be delivered immediately, bypassing long referral and manufacturing timelines, and is positioned for patients ineligible for auto CAR T or transplant.

• Dual-targeted CAR Ts and antibody-based regimens do not address fundamental access issues; vispa-cel targets the 75% of patients not reached by current standards.